A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which was developed for the generation of multivalent and multispecific antibody molecules. Dab-Fc comprises the variable domains of the anti-HER2 antibody trastuzumab and the anti-HER3 antibody 3-43 assembled into a diabody-like structure stabilized by C(H)1 and C-L domains and further fused to a human gamma 1 Fc region. The resulting Dab-Fc 2 x 3 molecule retained unhindered binding to both antigens and was able to bind both antigens sequentially. In cellular experiments, the Dab-Fc 2 x 3 molecule strongly bound to different tumor cell lines expressing HER2 and HER3 and was efficiently internalized. This was associated with potent inhibition of the proliferation and migration of these tumor cell lines. Furthermore, IgG-like pharmacokinetics and anti-tumoral activity were demonstrated in a xenograft tumor model of the gastric cancer cell-line NCI-N87. These results illustrate the suitability of our versatile Db-Ig platform technology for the generation of bivalent bispecific molecules, which has been successfully used here for the dual targeting of HER2 and HER3.

Automated summary

Dual targeting with bispecific antibodies is an emerging strategy in cancer therapy. A novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting HER2 and HER3 was developed from the Db-Ig platform, demonstrating potent anti-tumoral activity in cellular experiments and xenograft tumor models. The versatility of the Db-Ig platform technology in generating bivalent bispecific molecules for dual targeting of HER2 and HER3 was illustrated.